Multivariate analysis for overall survival, progression-free survival, and transplant-related mortality for all patients
Outcome . | Relative risk . | CI . | P . |
|---|---|---|---|
| Overall survival | 2.2-5.5 | < .001 | |
| Disease status at transplantation | 1.00 | ||
| CP1/CP2 | 3.4 | ||
| AP/BC | |||
| Prior transplantation | 0.9-2.7 | .08 | |
| No | 1.0 | ||
| Yes | 1.6 | ||
| Progression-free survival | |||
| Disease status at transplantation | 1.8-4.0 | < .001 | |
| CP1/CP2 | 1.00 | ||
| AP/BC | 2.7 | ||
| Fludarabine/busulphan/ATG | 0.4-1.0 | .06 | |
| No | 1.00 | ||
| Yes | 0.7 | ||
| TRM | |||
| Disease status at transplantation | 1.05-3.98 | .04 | |
| CP1/CP2 | 1.0 | ||
| AP/BC | 2.04 | ||
| Fludarabine/busulphan/ATG | 0.19-0.87 | .02 | |
| No | 1.0 | ||
| Yes | 0.41 |
Outcome . | Relative risk . | CI . | P . |
|---|---|---|---|
| Overall survival | 2.2-5.5 | < .001 | |
| Disease status at transplantation | 1.00 | ||
| CP1/CP2 | 3.4 | ||
| AP/BC | |||
| Prior transplantation | 0.9-2.7 | .08 | |
| No | 1.0 | ||
| Yes | 1.6 | ||
| Progression-free survival | |||
| Disease status at transplantation | 1.8-4.0 | < .001 | |
| CP1/CP2 | 1.00 | ||
| AP/BC | 2.7 | ||
| Fludarabine/busulphan/ATG | 0.4-1.0 | .06 | |
| No | 1.00 | ||
| Yes | 0.7 | ||
| TRM | |||
| Disease status at transplantation | 1.05-3.98 | .04 | |
| CP1/CP2 | 1.0 | ||
| AP/BC | 2.04 | ||
| Fludarabine/busulphan/ATG | 0.19-0.87 | .02 | |
| No | 1.0 | ||
| Yes | 0.41 |